مباشر

AgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.com Endpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapy Clinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected Future FierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EY FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market BioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studies Endpoints NewsA different approach to lowering healthcare costs CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity Clinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics BioPharma DiveStealthy startup Treeline plans a reverse merger 10x Genomics Blog10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz Endpoints NewsHow K Health moved AI chatbots into hospitals

Endpoints News ٩ يونيو ٢٠٢٦

Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success

Partners Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely brace...

Partners Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The companies ...